HEADACHE Act

Bill Number

H.R. 5536

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-09-19: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-30T08:06:46Z

AI-Generated Summary

Purpose of the Legislation

The HEADACHE Act (H.R. 5536) aims to improve research, diagnosis, treatment, and access to care for headache disorders—a group of conditions where headaches are the main symptom, affecting millions of Americans. It directs the Secretary of Health and Human Services (HHS) to launch a coordinated national effort to reduce the health, social, and economic burdens of these disorders, while promoting equity in care, especially for underserved groups.

Key Provisions

• National Headache Disorders Initiative (NHDI): HHS must establish and run this program to:
• Create a comprehensive strategy addressing medical, societal, and economic effects of headache disorders.
• Expand the workforce of clinicians and researchers specializing in these conditions.
• Coordinate with existing federal programs (e.g., NIH Pain Consortium, HEAL Initiative) to align resources.
• Prioritize research on faster, more accurate diagnoses and new treatments.
• Improve care protocols, including for related health issues (comorbid conditions, like other diseases occurring alongside headaches).
• Build better data systems to track headache disorders, reduce disparities in care, and support public health.
• Launch awareness campaigns to fight stigma and share social research findings.
• Collaborate with international organizations on global headache efforts.
• Advisory Council on Headache Disorders Research, Care, and Services: HHS must form this group to advise on headache-related policies. It includes:
• Federal representatives from agencies like NIH, FDA, CDC, VA, and others (at least one from each).
• 12 non-federal members, such as patient advocates (including those with migraine or other headaches), caregivers, specialized doctors (e.g., MDs, advanced practice providers, behavioral health experts), researchers, and reps from non-profit advocacy groups focused on headaches, with emphasis on minority and underserved communities.
• The council meets quarterly for the first two years, then as needed, and hosts an annual research meeting with federal and non-federal groups.
• Data Sharing: Federal agencies must share headache-related data (e.g., from health records, surveys) with HHS upon request, including standardized collection and integration with non-federal sources like patient registries.
• Annual Report to Congress: HHS must submit a yearly report covering:
• Evaluations of federal headache programs, their outcomes, and performance, including disparities by race, ethnicity, income, and location.
• Recommendations to cut costs (e.g., on Medicare), improve diagnostics and access, advance treatments, raise awareness, and reduce stigma.
• An updated national plan with short- and long-term goals.
• Sunset Clause: The entire act expires 5 years after enactment.

Significant Changes to Existing Law

This bill introduces entirely new federal programs and structures, as no prior comprehensive national initiative specifically targets headache disorders exists at this scale. It mandates coordination across agencies, resource allocation proportional to disease burden, and equity-focused data collection—changes not previously required. It builds on but expands existing pain research efforts (e.g., NIH Pain Consortium) by creating dedicated oversight, an advisory council, and reporting requirements tailored to headaches.

Potential Impacts

• Government Agencies: HHS and other federal bodies (e.g., NIH, CDC, VA) will face new duties to coordinate, share data, and allocate resources, potentially increasing budgets for headache research and care. This could streamline efforts but add administrative workload.
• Citizens: People with headache disorders (e.g., migraine, cluster headaches, those linked to COVID or brain injury) may gain better access to diagnosis, treatments, and support, especially in underserved groups like children, pregnant individuals, older adults, and minorities. Awareness campaigns could reduce stigma, improving quality of life and reducing economic costs from lost work or healthcare.
• International Relations: The bill encourages U.S. alignment with global headache efforts, potentially fostering collaborations on research and standards without direct foreign policy shifts.

Main Stakeholders Affected

• Patients and Caregivers: Individuals with headache disorders, their families, and advocates, particularly from vulnerable or underrepresented communities.
• Healthcare Providers: Specialists (e.g., neurologists, pain experts), primary care doctors, and behavioral health professionals who treat headaches.
• Researchers and Non-Profits: Scientists focused on headaches and organizations advocating for patients.
• Federal Agencies: HHS (lead role), NIH, FDA, CDC, VA, DoD, CMS, and others involved in health research, care, or funding.
• Broader Society: Employers and the economy, due to reduced productivity losses from untreated headaches.

Notable Legal, Constitutional, or Political Implications

• Legal: Establishes enforceable duties for HHS and agencies under administrative law, with data-sharing requirements that respect privacy laws (e.g., HIPAA, though not explicitly addressed). The 5-year sunset provides a trial period, allowing Congress to extend or modify based on results.
• Constitutional: Aligns with Congress's authority to regulate public health and spend on welfare (Spending Clause), promoting equal protection by addressing care disparities without raising equal protection challenges.
• Political: Highlights bipartisan focus on chronic pain conditions, potentially influencing future health equity legislation. The temporary nature limits long-term commitments, but annual reports could build momentum for permanent programs if effective. No major controversies anticipated, as it emphasizes coordination over new spending mandates.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Trahan, Lori [D-MA-3]

Cosponsors (44)

Rep. Budzinski, Nikki [D-IL-13], Rep. Moulton, Seth [D-MA-6], Rep. Kelly, Robin L. [D-IL-2], Rep. Foushee, Valerie P. [D-NC-4], Rep. Fitzpatrick, Brian K. [R-PA-1], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Gottheimer, Josh [D-NJ-5], Rep. Norcross, Donald [D-NJ-1], Rep. Nadler, Jerrold [D-NY-12], Rep. Salinas, Andrea [D-OR-6], Rep. Lynch, Stephen F. [D-MA-8], Rep. McBride, Sarah [D-DE-At Large], Rep. Thanedar, Shri [D-MI-13], Rep. Carbajal, Salud O. [D-CA-24], Rep. Jackson, Jonathan L. [D-IL-1], Rep. Brownley, Julia [D-CA-26], Rep. Mackenzie, Ryan [R-PA-7], Rep. Sewell, Terri A. [D-AL-7], Rep. Tlaib, Rashida [D-MI-12], Rep. Ryan, Patrick [D-NY-18], Rep. Johnson, Julie [D-TX-32], Rep. Pressley, Ayanna [D-MA-7], Rep. Ross, Deborah K. [D-NC-2], Rep. Houlahan, Chrissy [D-PA-6], Rep. Mrvan, Frank J. [D-IN-1], Rep. McGovern, James P. [D-MA-2], Rep. Lawler, Michael [R-NY-17], Rep. Hayes, Jahana [D-CT-5], Rep. Goldman, Daniel S. [D-NY-10], Rep. Vasquez, Gabe [D-NM-2], Rep. Friedman, Laura [D-CA-30], Rep. Walkinshaw, James R. [D-VA-11], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Bynum, Janelle S. [D-OR-5], Rep. Khanna, Ro [D-CA-17], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Tonko, Paul [D-NY-20], Rep. Balint, Becca [D-VT-At Large], Rep. Pingree, Chellie [D-ME-1], Rep. Smith, Adam [D-WA-9], Rep. Malliotakis, Nicole [R-NY-11], Rep. LaLota, Nick [R-NY-1], Rep. Stevens, Haley M. [D-MI-11], Rep. Kelly, Mike [R-PA-16]

Recent Actions

• 2025-09-19: Referred to the House Committee on Energy and Commerce.
• 2025-09-19: Introduced in House
• 2025-09-19: Introduced in House

Bill Versions

• Headache Education, Access, Diagnosis, and Care Health Equity Act — issued 2025-09-19 — PDF (10 pages)